Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 9 Meters Biopharma Inc. NMTR

9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003 and others.


Recent & Breaking News (NDAQ:NMTR)

9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

Accesswire November 29, 2022

9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy

Accesswire November 14, 2022

9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022

Accesswire November 8, 2022

9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting

Accesswire October 24, 2022

9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

Accesswire October 18, 2022

9 Meters Biopharma Announces 1-for-20 Reverse Stock Split

Accesswire October 17, 2022

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

Accesswire September 26, 2022

9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Accesswire September 6, 2022

9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) Congress

Accesswire September 1, 2022

9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference

Accesswire August 31, 2022

9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022

Accesswire August 15, 2022

9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022

Accesswire July 6, 2022

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

Accesswire June 30, 2022

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

Accesswire June 30, 2022

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

Accesswire June 21, 2022

9 Meters Biopharma to Participate in the 2022 BIO International Convention

Accesswire June 13, 2022

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

Accesswire May 19, 2022

9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis

Accesswire May 18, 2022

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

Accesswire May 16, 2022

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

Accesswire May 5, 2022